ClinicalTrials.gg

Program

Polymyxin B

Also written as “Polymyxin B (50 mg)” and “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”.

Its studies are mostly in Pneumonia, Bacterial · Eczema, led by 3 companies.

Furthest: phase 3, since Jan 7, 20264 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioVersys SAS22 open or runningphase 3since Jan 7, 2026Jan 7, 2026Dec 30, 2027phase 3 · NCT07326540
EMS10 open or runningphase 3since Sep 5, 2011Sep 5, 2011none ahead
TTY Biopharm10 open or runningphase 1since Mar 29, 2022Mar 29, 2022none ahead

Also a collaborator on its studies: bioversys-ag.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2011First study: phase 3 study in EczemaNew to EMSEMS · NCT01429701 · 76 enrolled
  2. Mar 29, 2022TTY Biopharm's first study: phase 1 study in Antibiotic ToxicityNew to TTY BiopharmTTY Biopharm · NCT05359627 · 22 enrolled · Taiwan
  3. Jan 7, 2026BioVersys SAS's first study: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)New to BioVersys SASBioVersys SAS · NCT07326540 · 248 planned · Georgia
  4. Apr 28, 2026Phase 1 study in Healthy Adult ParticipantsBioVersys SAS · NCT07580586 · 16 planned · Austria

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)BioVersys SAS · NCT07326540

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cell outer membrane inhibitor”ChEMBL 37, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07580586Healthy Adult Participants · Austria1RecruitingBioVersys SASSep 30, 202616
NCT07326540Hospital Acquired Bacterial Pneumonia (HABP) · Georgia3RecruitingBioVersys SASDec 30, 2027248
NCT05359627Antibiotic Toxicity · Taiwan1CompletedTTY BiopharmMar 3, 202322
NCT01429701Eczema3CompletedEMSJun 201276

How it is read

Names in the registry

  • “Polymyxin B”, 2 entries
  • “Polymyxin B (50 mg)”, 1 entry
  • “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.